The investment would be “significant” in the range of “tens of millions of dollars”, the companies said, but did not disclose any specific numbers, including proposed capacities, citing “confidentiality”. The JV will combine SGD Pharma’s vial-converting expertise with Corning’s velocity vial platform. It intends to localise the supply chains and enable easier adoption of the technology by pharma customers.
